Psychedelic Mushrooms Are Closer to Medicinal Use (It’s Not Just Your Imagination)

Researchers from Johns Hopkins University have recommended that psilocybin, the active compound in hallucinogenic mushrooms, be reclassified for medical use, potentially paving the way for the psychedelic drug to one day treat depression and anxiety and help people stop smoking. The suggestion to reclassify psilocybin from a Schedule I drug, with no known medical benefit,…

Details

Memorial Sloan Kettering’s Chief Executive Resigns From Merck’s Board of Directors

This article was reported and written in a collaboration with ProPublica, the nonprofit journalism organization. Dr. Craig B. Thompson, the chief executive of Memorial Sloan Kettering Cancer Center, said Tuesday that he would resign his seats on the boards of drug maker Merck and another public company, the latest fallout from a widening institutional reckoning…

Details